Clinical trials: Covid-19 Pneumonia
Covid19
Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg)
Coronavirus Disease 2019 (COVID-19) is a newly emerged disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04586413
- Testing
- No intervention - quality of life measure
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Medialis Ltd.
Covid19
A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers
This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via the…
- Trial name
- NCT04839042
- Testing
- SC-Ad6-1
- Where
- Australia
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Moat Biotechnology Corporation
COVID-19
JINZHEN for Treatment of Mild to Moderate COVID-19
JINZHEN is a botanical drug that contains eight chemical constituents extracted from plant, mineral and animal origin raw materials.
- Trial name
- NCT05092503
- Testing
- JINZHEN Granules for Oral Solution
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Lianyungang Kanion Group, Ltd.
SARS CoV 2 Infection
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.
The objective of the study is to evaluate the efficacy and safety of two different doses of raloxifene orally administered compared to placebo in patients with early diagnosis of paucisymptomatic COVID-19.
- Trial name
- NCT05172050
- Testing
- Raloxifene
- Where
- 11 sites in France, Italy and 1 more
- Volunteers
- 61 people
- Sponsor
- Dompé Farmaceutici S.p.A
COVID-19
Efficacy of KOVIR Capsule in the Combination Regimen With Background Treatment in COVID-19 Patients
The acute pneumonia pandemic caused by a new strain of corona virus 2019, namely as COVID-19 by the World Health Organization (WHO), is a pandemic caused by SARS-CoV-2 virus.
- Trial name
- NCT05044650
- Testing
- KOVIR capsule combined with background treatment
- Where
- Vietnam
- Volunteers
- 1,000 people
- Sponsor
- Sao Thai Duong Joint Stock Company
Fever, Pneumonia
COVID-19 Epidemic Response Study
A national, observational, longitudinal, non-interventional program aiming to identify prognostic parameters, to investigate the kinetics of the immune response, and to identify predictive biomarkers in SARS-CoV-2 infected…
- Conditions
- Fever, Pneumonia, Cough
- Trial name
- COVeR (NCT04357496)
- Sponsor
- CENTOGENE GmbH Rostock
COVID-19
Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above
This trial adopts a randomized, double-blind and positive control design, it is planned to recruit 1800 healthy participants who have been vaccinated with 2/3 doses of COVID-19 inactivated vaccine or mRNA vaccine for 3 months.
- Trial name
- COVID-19 (NCT05382871)
- Testing
- BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Hong Kong
- Volunteers
- 1,804 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COVID-19 Pandemic
Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis spore extract which contain Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05158855
- Testing
- Bacillus subtilis spore extract
- Where
- Macau
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited
SARS-CoV-2 (COVID-19) Infection
Safety, Tolerability, and Systemic Exposure of Apo-Si- K170A-C76 in Healthy Volunteers
The goal of this First in Human Phase 1 clinical trial is to to assess the safety, tolerability, and systemic exposure of single, twice daily (BID) doses and repeated BID doses of ascending dosing by intranasal administration of…
- Trial name
- BID (NCT07095049)
- Testing
- Apo-Si-K170A-C76
- Where
- Israel
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Interna Therapeutics Ltd.
COVID-19
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of therecombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants…
- Trial name
- NCT04904471
- Testing
- Recombinant COVID-19 vaccine (Sf9 cells)
- Where
- 24 sites in Indonesia, Kenya and 3 more
- Volunteers
- 39,663 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19 Pneumonia
A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia
This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) compared with placebo and of UTTR1147A compared with placebo, in combination with…
- Trial name
- COVASTIL (NCT04386616)
- Testing
- MSTT1041A, UTTR1147A
- Where
- 41 sites in United States, Brazil and 2 more
- Volunteers
- 396 people
- Sponsor
- Genentech, Inc.
COVID-19
Effectiveness of Chinese COVID-19 Vaccines in Latin America and the Caribbean
This multi-country study seeks to collect real-world evidence (RWE), from Latin American and Caribbean countries, on the effectiveness of China-made COVID-19 vaccines in different populations, against different clinical outcomes…
- Trial name
- NCT05475704
- Where
- 5 sites in Argentina, Colombia and 2 more
- Volunteers
- 59 people
- Sponsor
- P95
COVID19, ARDS
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
- Trial name
- RESOLVE (NCT04468971)
- Testing
- CK0802
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cellenkos, Inc.
Cytokine Release Syndrome in COVID-19-induced Pneumonia
Canakinumab MAP in COVID-19 Pneumonia With CRS
This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia
- Trial name
- NCT04476706
- Testing
- canakinumab
- Sponsor
- Novartis Pharmaceuticals
COVID-19
Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19
This is a randomized, Open, control phase Ⅳ clinical trial of inactivated COVID-19 vaccine manufactured by Sinovac Research \& Development Co., Ltd,Beijing institute of Biological Products Co.,Ltd and Wuhan Institute of…
- Trial name
- NCT05165732
- Testing
- Experimental vaccine 1, Experimental vaccine 2, Experimental vaccine 3
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation
This study is a randomized, double-blind, placebo-controlled I/II clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation in adults 18…
- Trial name
- NCT04840992
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
MRSA Bloodstream Infection, MRSA Bacteremia
Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia
This is an open-label, expanded access study of exebacase used in addition to antistaphylococcal antibiotics in adult patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)…
- Conditions
- MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis, Covid19
- Trial name
- NCT04597242
- Testing
- Exebacase
- Where
- 2 sites in United States
- Sponsor
- ContraFect
COVID-19
A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell)
The study was designed as a randomized, blind and controlled trial. A total of 300 patients aged 18 and above who were immunized with recombinant novel coronavirus protein vaccine (CHO cell) for more than 4 months (60 patients…
- Trial name
- NCT05616754
- Testing
- Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells), Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
- Where
- Uzbekistan
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
This Phase 2b study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of sotrovimab in pediatric participants from birth to less than (<)18 years old with mild-to-moderate Coronavirus Disease-2019…
- Trial name
- COMET-PACE (NCT05124210)
- Testing
- Sotrovimab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
COVID-19 Pneumonia
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314
A Double-blind, Multi-center, Multi-regional, Randomized controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed with COVID-19
- Trial name
- NCT04871646
- Testing
- CKD-314+SOC
- Where
- South Korea
- Volunteers
- 586 people
- Sponsor
- Chong Kun Dang Pharmaceutical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.